Elite Pharmaceuticals Inc insiders have been one-way buyers this past year: one person put roughly $8,700 into the stock and nobody sold on the open market.
Biggest single buyer: Dash Barry H, Director, with roughly $8,700.
Big money check: 1 institutions held ELTP as of Q2 2026, and more funds bought than sold. Looking at the quarterly pattern: Last full quarter: net buying by insiders. Insiders bought in 2 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Sep 10, 2026 | Dash Barry H | Director | Buy | 30,000 | $0.29 | $9K | SEC |
| Oct 3, 2025 | Plassche Douglas | Executive Officer | Sell | 800,000 | $0.62 | $496K | SEC |
| Aug 26, 2025 | ELITE PHARMACEUTICALS INC /NV/ | Executive Officer | Sell | 500,000 | $0.52 | $260K | SEC |
| Jul 25, 2025 | Kirkov Kirko | Executive Officer | Buy | 16,366 | $0.59 | $10K | SEC |
| Jul 10, 2025 | Plassche Douglas | Executive Officer | Sell | 200,000 | $0.58 | $116K | SEC |
| Oct 28, 2024 | Plassche Douglas | Executive Officer | Sell | 800,000 | $0.49 | $392K | SEC |
| Oct 28, 2024 | Plassche Douglas | Executive Officer | Sell | 333,932 | $0.51 | $170K | SEC |
In the last 12 months Elite Pharmaceuticals Inc insiders made open-market purchases worth about $8,700 and sales worth about $0. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in ELTP was filed on 2026-09-10.
1 investment managers reported holding ELTP in SEC Form 13F filings for Q2 2026.
No congressional trades in ELTP were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).